4,4-Propylenebis(Piperazine-2,6-Dione) 4,4-(丙烷-1,2-二基)双(哌嗪-2,6-二酮)
CAS 21416-67-1 MFCD00430424
化学结构图
SMILES: CC(CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
化学属性
| Mol. Formula | C11H16N4O4 |
|---|---|
| Mol. Weight | 268 |
别名和识别编码
| Chemical Name | 4,4-Propylenebis(Piperazine-2,6-Dione) |
|---|---|
| CAS Number | 21416-67-1 |
| Alfabeta Name | PROPANEDIYLBISPIPERAZINEDIONE 441226(())-----,,,' |
| MDL Number | MFCD00430424 |
| Synonym | Razoxin Troxozone (±)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane (±)-1,2-Bis(3,5-dioxopiperazinyl)propane 1,2-Bis(3,5-dioxo-1-piperazinyl)propane 4,4'-Propylenebis(2,6-piperazinedione) ICI 59118 ICRF 159 NSC 129943 Razoxin Tepirone Troxozone 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis- ICRF 159 ICI 59118 Razoxane |
| EC Number | 244-379-2 |
| Wiswesser Line Notation | T6VMV ENTJ EY1&1- ET6VMV ENTJ |
| Beilstein Registry Number | 0821182 |
| Chemical Name Translation | 4,4-(丙烷-1,2-二基)双(哌嗪-2,6-二酮) |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Apoptosis and Cell Cycle, Cell Biology, Cell Signaling and Neuroscience, DNA Repair Regulators, DNA metabolism
- {SNA} Apoptosis and Cell Cycle, Bioactive Small Molecule Alphabetical Index, DNA Repair Regulators, DNA metabolism, R, 生物活性小分子, 细胞信号转导和神经科学, 细胞生物学
安全信息
TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 3650 mg/kg/2Y-I TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia REFERENCE : LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 2,1085,1987
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 693 mg/kg/77W-I TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia REFERENCE : LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 2,1343,1981
TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 4650 mg/kg/2Y-C TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia REFERENCE : LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 2,1343,1981
TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 2693 mg/kg/3Y-C TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Skin and Appendages - tumors REFERENCE : BJDEAZ British Journal of Dermatology. (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.63- 1951- Volume(issue)/page/year: 109,675,1983
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported SPECIES OBSERVED : Human - woman DOSE/DURATION : 600 mg/kg/34W-I TOXIC EFFECTS : Blood - leukopenia REFERENCE : BJDEAZ British Journal of Dermatology. (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.63- 1951- Volume(issue)/page/year: 113,131,1985
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 500 mg/kg TOXIC EFFECTS : Tumorigenic - active as anti-cancer agent REFERENCE : CPBTAL Chemical and Pharmaceutical Bulletin. (Japan Pub. Trading Co., USA, 1255 Howard St., San Francisco, CA 94103) V.6- 1958- Volume(issue)/page/year: 29,1594,1981
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 3650 mg/kg/2Y-I TOXIC EFFECTS : Kidney, Ureter, Bladder - hematuria Blood - aplastic anemia REFERENCE : LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 2,1085,1987
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported SPECIES OBSERVED : Human - man DOSE/DURATION : 6467 mg/kg/6Y-I TOXIC EFFECTS : Blood - normocytic anemia Blood - thrombocytopenia REFERENCE : BJDEAZ British Journal of Dermatology. (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.63- 1951- Volume(issue)/page/year: 113,131,1985
TYPE OF TEST : Cytogenetic analysis ROUTE OF EXPOSURE : Oral TEST SYSTEM : Rodent - hamster DOSE/DURATION : 100 mg/kg REFERENCE : BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947- Volume(issue)/page/year: 52,725,1985
TYPE OF TEST : Unscheduled DNA synthesis TEST SYSTEM : Rodent - hamster Fibroblast DOSE/DURATION : 1 mmol/L REFERENCE : JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963- Volume(issue)/page/year: 20,630,1977
TYPE OF TEST : DNA inhibition TEST SYSTEM : Human Lymphocyte DOSE/DURATION : 20 mg/L REFERENCE : I
TYPE OF TEST : Mutation test systems - not otherwise specified TEST SYSTEM : Human Lymphocyte DOSE/DURATION : 20 mg/L REFERENCE : INNDDK Investigational New Drugs. The Journal of New Anticancer Agents. Kluwer Academic Pub., POB 358, Accord Stn., Hingham, MA 02018) V.1- 1983- Volume(issue)/page/year: 1,283,1983
TYPE OF TEST : Micronucleus test ROUTE OF EXPOSURE : Intraperitoneal TEST SYSTEM : Rodent - mouse DOSE/DURATION : 200 mg/kg REFERENCE : BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947- Volume(issue)/page/year: 52,725,1985
TYPE OF TEST : DNA inhibition TEST SYSTEM : Rodent - hamster Fibroblast DOSE/DURATION : 1 mmol/L REFERENCE : JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963- Volume(issue)/page/year: 20,630,1977
